Physician profile
Naoto T Ueno
NPI 1851497770
$288,130.89
in general payments reported to CMS, 2019-2025
33 companies · $29K in 2025
The $29K reported for 2025 was more than what 91% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $51K · 2020: $40K · 2021: $23K · 2022: $46K · 2023: $45K · 2024: $54K · 2025: $29K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $74K · Consulting Fee: $49K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,520 · Food and Beverage: $2,176.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $74,147.88 |
| Consulting Fee | $49,066.45 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,520.00 |
| Food and Beverage | $2,175.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Chugai Pharmaceutical Co., Ltd. | $87,539.00 | 2019-2025 | |
| Kyowa Kirin Co., Ltd | $67,777.21 | 2019-2023 | |
| Daiichi Sankyo INC. | $28,138.40 | 2019-2024 | Enhertu |
| Lilly USA, LLC | $26,157.98 | 2023-2024 | |
| Daiichi Sankyo Company Ltd | $18,525.00 | 2023 | |
| Sysmex America, INC. | $9,589.72 | 2019-2022 | |
| Sumitomo Pharma Co., Ltd. | $8,601.44 | 2021-2022 | |
| Astrazeneca Pharmaceuticals Lp | $5,811.07 | 2019-2025 | Truqap |
| Pfizer INC. | $5,351.43 | 2019-2025 | |
| Gilead Sciences, INC. | $5,128.23 | 2021-2025 | Trodelvy |
| Eisai Co., Ltd. | $3,593.75 | 2021 | |
| Amgen INC. | $3,395.00 | 2019 | |
| Takeda Pharmaceutical Company, Limited | $2,160.00 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $2,160.00 | 2021 | |
| Immunomedics, INC. | $2,100.00 | 2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $2,031.25 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $2,000.20 | 2022-2023 | |
| E.R. Squibb & Sons, L.L.C. | $1,985.00 | 2022-2025 | |
| Genentech USA, INC. | $1,899.34 | 2024-2025 | Itovebi, Polivy |
| Taiho Oncology, INC. | $1,684.00 | 2019 | |
| Telix Pharmaceuticals | $1,500.00 | 2024 | Illuccix |
| Caris Mpi, INC. | $313.43 | 2025 | Mi Cancer Seek |
| Novartis Pharmaceuticals Corporation | $251.09 | 2023-2025 | |
| Janssen Scientific Affairs, LLC | $145.00 | 2024 | Erleada, Akeega |
| Astrazeneca Uk Limited | $135.00 | 2023 | Enhertu |
| Novocure INC. | $53.67 | 2024 | Optune |
| Genentech, INC. | $45.24 | 2023 | |
| Puma Biotechnology, INC. | $37.33 | 2019 | |
| Accord Healthcare, INC. | $22.11 | 2025 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Naoto Ueno listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.